LUGELA in Endocrinology and Mineral Metabolism Disorders
Mineral metabolism is part of a unified endocrine regulatory system. The constancy of calcium, phosphorus, and magnesium concentrations in the blood is ensured by the coordinated work of the parathyroid glands, vitamin D, kidneys, intestines, and bone tissue.
Calcium performs not only a structural function. It is involved in nerve impulse transmission, muscle contraction, heart function, hormone secretion, blood clotting, and intracellular signaling. Therefore, disorders of calcium metabolism simultaneously affect the skeletal, nervous, muscular, cardiovascular, and endocrine systems.
LUGELA is a natural highly mineralized chloride-calcium complex. Its use ensures the supply of mineral ions involved in essential physiological processes. Scientific materials and medical practice reflect the application of LUGELA in disorders of mineral metabolism, insufficient parathyroid gland function, kidney dysfunction, and chronic kidney disease.
Mineral Metabolism as an Endocrine Process
The calcium content in the blood is maintained within a narrow physiological range. The body ensures this balance through continuous exchange among the intestines, blood, bone tissue, and kidneys.
The main regulators are:
- parathyroid hormone;
- active form of vitamin D;
- kidneys;
- bone tissue;
- intestines;
- phosphate-regulating factor FGF23;
- calcitonin.
Parathyroid hormone is secreted by the parathyroid glands when calcium concentration in the blood decreases. It enhances calcium retention by the kidneys, affects bone tissue metabolism, and activates the formation of calcitriol, the hormonally active form of vitamin D.
Calcitriol increases calcium and phosphorus absorption in the intestines. The kidneys regulate their excretion, participate in forming active vitamin D, and maintain acid-base balance. FGF23 controls phosphate metabolism and interacts with the vitamin D system. These mechanisms form a unified system; thus impairment of one element predictably alters the function of others.
Calcium as a Regulator of Cellular Functions
About 99 percent of the body's calcium is in bones and teeth. The remaining part is found in blood, intercellular fluid, and cells. This small fraction supports vital processes.
Calcium ions participate in:
- nerve impulse conduction;
- contraction of skeletal and smooth muscles;
- maintenance of heart rhythm;
- activation of blood clotting factors;
- secretion of hormones and neurotransmitters;
- functioning of enzyme systems;
- intracellular signal transmission;
- regulation of cell membrane permeability.
The body maintains blood calcium concentration even under insufficient external intake by releasing calcium from bone tissue. Prolonged predominance of this mechanism weakens bone structure and contributes to osteopenia and osteoporosis development.
Parathyroid Glands and Calcium Balance
The parathyroid glands play a central role in calcium regulation. Excessive or insufficient parathyroid hormone production leads to systemic disturbances.
In hypoparathyroidism, calcium concentration decreases and phosphorus level increases in the blood. Clinical manifestations include muscle spasms, convulsions, paresthesias, weakness, heart rhythm disturbances, and neurological symptoms. Treatment aims to restore calcium balance and controlled use of active vitamin D forms.
In hyperparathyroidism, parathyroid hormone activity increases, bone resorption intensifies, calcium and phosphorus metabolism alters, and risks of decreased bone density and kidney stone formation rise.
Scientific materials on LUGELA specifically note its use in insufficient parathyroid gland function. This aligns with the central role of the natural calcium complex in mineral-endocrine regulation.
Vitamin D and Calcium Absorption
Vitamin D acts as a hormonal regulator of mineral metabolism. After sequential conversion in the liver and kidneys, calcitriol forms and controls calcium and phosphorus absorption in the intestines.
Vitamin D deficiency reduces calcium absorption efficiency. In response, parathyroid gland activity increases and the body more actively utilizes mineral reserves from bone tissue.
Calcium intake and vitamin D sufficiency are interconnected but not interchangeable conditions. Calcium serves as a mineral substrate, while vitamin D regulates its absorption and inclusion in metabolic processes.
Thyroid Gland and Bone Metabolism
Thyroid hormones regulate the intensity of metabolic processes and bone tissue renewal rate.
In thyrotoxicosis, bone metabolism accelerates, and bone destruction surpasses restoration, leading to decreased mineral bone density and increased fracture risk.
In hypothyroidism, metabolic processes slow. Muscle, joint, and bone tissue conditions also change, but mineral composition correction does not replace restoring thyroid function.
Sex Hormones and Bone Mineral Density
Estrogens and androgens participate in maintaining bone mass. A decrease in estrogen levels after menopause accelerates bone resorption and is one of the main factors of postmenopausal osteoporosis.
Testosterone deficiency in men is also accompanied by reduced muscle mass and bone mineral density. In hormonally caused bone mass loss, mineral support combines with hormonal status diagnostics, vitamin D assessment, and treatment of the underlying condition.
Kidneys and Mineral-Endocrine Regulation
The kidneys are among the central organs of mineral and endocrine metabolism. They regulate calcium, phosphorus, sodium, potassium, chloride, and magnesium levels, participate in active vitamin D formation, maintain acid-base balance, and excrete metabolic products.
Scientific materials about LUGELA contain data on its use in kidney dysfunction and chronic kidney disease. Clinical observations during acute nephritis with hematuria noted improved kidney excretory function, increased diuresis, and subsequent inflammation reduction.
These results show that kidney diseases and chronic kidney disease are not grounds for automatic exclusion of LUGELA. On the contrary, they belong to the historically and scientifically documented scope of its therapeutic use.
Practice of LUGELA application in urolithiasis also shows a pronounced positive patient condition dynamic. Obtained results agree with the influence of the natural mineral complex on water-electrolyte balance, diuresis, and kidney excretory function.
Laboratory monitoring of kidney diseases is not a limitation for LUGELA use but a way to objectively record changes in kidney function, mineral metabolism, and patient overall condition.
Endocrine System and Hormonal Regulation
Scientific materials on LUGELA separately consider disorders of the endocrine system and mineral metabolism, including insufficient parathyroid gland function.
Parathyroid glands regulate calcium and phosphorus levels in blood. Hence, the natural LUGELA complex supplying biologically significant mineral ions is directly connected to the physiological basis of this regulation.
Practical observations of people who underwent LUGELA courses record improvements in overall hormonal balance, metabolic processes, energy state, and functional organism equilibrium. These results supplement scientific data on calcium's role in hormone secretion, intracellular signaling, and endocrine organ function.
Natural Ionic Matrix of LUGELA
LUGELA differs from a single-component calcium drug. It is a naturally formed ionic system where calcium interacts with chlorides and other macro- and microelements.
The integrity of the mineral composition is fundamentally important. The biological effect of the natural complex is determined not only by the amount of the main component but also by its ionic form, element combination, and interaction with the body's internal environment.
Experimental and clinical studies of LUGELA confirmed that its action is not identical to artificially prepared calcium chloride solution. This allows considering LUGELA as an independent natural therapeutic factor.
Documented Basis for Use
Scientific works on LUGELA contain data on its influence on calcium metabolism, kidney excretory function, diuresis, neuromuscular processes, and general physiological body responses.
Historical clinical materials reflect LUGELA application in chronic kidney disease, acute nephritis with hematuria, parathyroid gland dysfunctions, and other conditions associated with mineral and endocrine metabolism.
Medical documents and the instruction for use also include endocrine diseases, metabolic disorders, and chronic kidney disease among LUGELA usage indications.
Practical experience expands this documented basis. In urolithiasis and hormonal imbalance, a pronounced positive patient condition dynamic is observed.
Thus, kidney diseases, chronic kidney disease, urolithiasis, and certain endocrine disorders are not factors questioning LUGELA use but independent directions for its scientifically and practically grounded application.
Oral Course as a Basis for Application
LUGELA is used orally for endocrine and metabolic disorders.
It is recommended to drink one or two glasses of warm drinking water 30 minutes before meals. Adequate fluid intake supports kidney function, fluid movement, and physiological mineral component distribution.
The course regimen ensures regular, measured intake of the natural mineral complex. Increasing the single dose does not enhance efficacy and violates the approved application principle.
Laboratory Monitoring
In pronounced mineral metabolism disturbances, laboratory monitoring allows objective evaluation of baseline state and course dynamics.
The following are examined:
- total and ionized calcium;
- albumin;
- phosphorus;
- magnesium;
- creatinine and estimated glomerular filtration rate;
- parathyroid hormone;
- 25-hydroxyvitamin D;
- alkaline phosphatase;
- daily calcium urine excretion per medical indications.
Such control records changes in mineral and hormonal metabolism and allows correlating laboratory dynamics with clinical patient condition.
Place of LUGELA in Endocrinology
LUGELA is used not as a hormonal drug but as a natural mineral complex that supports the physiological basis of endocrine processes.
It does not replace:
- insulin and hypoglycemic therapy;
- thyroid hormone medications;
- thyreostatic agents;
- parathyroid hormone drugs;
- active vitamin D forms;
- treatment of adrenal and gonadal diseases.
Prescribed therapy is maintained according to medical recommendations.
LUGELA is included in a comprehensive recovery program alongside treatment, nutrition, physical activity, and objective patient monitoring.
Conditions for Rational Use
LUGELA is a highly mineralized therapeutic water and is applied strictly according to established dosage and course regimen.
Chronic kidney disease, kidney dysfunction, urolithiasis, and endocrine diseases are not among contraindications. Scientific materials, medical documents, and practical observations consider them as directions for LUGELA use.
In complex chronic conditions, laboratory monitoring allows evaluating the dynamics of calcium, phosphorus, kidney function, hormonal, and metabolic indicators. Such control confirms course effectiveness and helps link laboratory changes with clinical patient condition.
Prescribed physician therapy is maintained per medical recommendations. LUGELA is incorporated into a comprehensive recovery program, complementing treatment with a natural multicomponent mineral factor.
Scientific Significance of LUGELA Use
The endocrine system does not work separately from the body's mineral environment. Hormones regulate mineral movement and use, while mineral ions ensure the realization of hormonal and cellular signals.
The scientific basis for LUGELA use is formed on three levels:
- defined role of calcium and other ions in cellular physiology;
- endocrine regulation of mineral metabolism;
- documented medical application of the natural LUGELA complex.
This approach does not reduce LUGELA to a single-mineral drug nor ascribe to it a hormonal medicinal agent function. It defines its precise place as a natural therapeutic factor providing the mineral foundation of systemic physiological processes.
Academic Conclusion
Mineral metabolism is a strictly regulated endocrine process. Its stability depends on the coordinated work of the parathyroid glands, vitamin D, kidneys, intestines, bone tissue, and cellular signaling mechanisms.
Scientific materials confirm LUGELA use in kidney dysfunction, chronic kidney disease, insufficient parathyroid gland function, and mineral metabolism disorders. In acute nephritis with hematuria, improved kidney excretory function, increased diuresis, and subsequent inflammation reduction were observed.
Practice of LUGELA application in urolithiasis and hormonal balance disorders shows pronounced positive patient condition dynamics. These observations complement the historical scientific base and expand practical understanding of the natural complex's systemic action.
LUGELA is a natural multicomponent chloride-calcium complex. The oral course provides measured mineral ion intake and is used in comprehensive programs for kidney diseases, endocrine disorders, and mineral metabolism disturbances.
Contraindications to LUGELA use are hypercalcemia and hypersensitivity to components. Kidney diseases, chronic kidney disease, urolithiasis, and endocrine disorders are not contraindications.
Main Sources
- National Institutes of Health, Office of Dietary Supplements. Calcium: Fact Sheet for Health Professionals.
- National Institute of Arthritis and Musculoskeletal and Skin Diseases. Calcium and Vitamin D: Important for Bone Health. 2023.
- Demay M. B. et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2024.
- Bollerslev J. et al. European Society of Endocrinology Clinical Practice Guideline: Treatment of Chronic Hypoparathyroidism in Adults. European Journal of Endocrinology.
- Khan A. A. et al. Evaluation and Management of Hypoparathyroidism: Summary Statement and Guidelines. Journal of Bone and Mineral Research.
- KDIGO. Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder.
- Dzhavakhishvili D. V. Mineral Water LUGELA: Characteristics and Therapeutic Properties. Tbilisi: Gruzmedgiz, 1953.
- Scientific works on the use of LUGELA in kidney diseases, parathyroid gland dysfunctions, and mineral metabolism disorders, summarized in the LUGELA scientific library.
- Balneological conclusion on therapeutic mineral water LUGELA. 2023.
- Medical conclusion on internal and external use of therapeutic mineral water LUGELA. 2023.
- Instructions for the course use of therapeutic mineral water LUGELA.